Outcome of allogeneic stem cell transplantation in patients with chronic myeloid leukaemia treated with second generation tyrosine kinases inhibitors after imatinib failure

被引：0
|
作者：
Palandri, F.
Breccia, M. [1 ]
Iori, A. P. [1 ]
Bonifazi, F.
Latagliata, R. [1 ]
Colaci, E.
Torelli, G. F. [1 ]
Castagnetti, F.
Valle, V. [1 ]
Usai, S. [1 ]
Martinelli, G.
Dell'Agnola, C. [2 ]
Cingarlini, S. [2 ]
Rosti, G.
Baccarani, M.
Alimena, G. [1 ]
机构：
[1] Univ Roma La Sapienza, Rome, Italy
[2] Policlin GB Rossi, Verona, Italy
来源：
BONE MARROW TRANSPLANTATION | 2009年 / 43卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S261 / S261
页数：1
相关论文
共 50 条
  • [21] VALIDATION OF A PROGNOSTIC SCORING SYSTEM IN PATIENTS TREATED WITH SECOND-GENERATION TYROSINE KINASE INHIBITORS FOR CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE AFTER IMATINIB FAILURE
    Boquimpani, C.
    Schaffel, R.
    Graca, D.
    Mesquita, C.
    Peixoto, D.
    Madeira, T.
    Wendling, P.
    Eller, F.
    Biasoli, I.
    Spector, N.
    HAEMATOLOGICA, 2013, 98 : 553 - 553
  • [22] Imatinib mesylate therapy in patients with chronic myeloid leukaemia previously treated with autologous stem cell transplantation
    Cortés, M
    Sureda, A
    Martino, R
    Aventin, A
    Nomdedeu, J
    Briones, J
    Valcárcel, D
    Brunet, S
    Sierra, J
    BONE MARROW TRANSPLANTATION, 2004, 33 : S151 - S151
  • [23] Complete cytogenetic response in patient with relapse of chronic myeloid leukaemia treated with glivec after second allogeneic stem cell transplantation
    Elez, M
    Stamatovic, D
    Tukic, L
    Todoric-Zivanovic, B
    Balint, B
    Glavicic, V
    Simic, L
    Ristic, L
    Malesevic, M
    BONE MARROW TRANSPLANTATION, 2005, 35 : S382 - S382
  • [24] Effect of prior therapy with nilotinib or dasatinib on the outcome after allogeneic stem cell transplantation for patients with chronic myeloid leukaemia
    Schleuning, M.
    Scholten, M.
    van Biezen, A.
    Nagler, A.
    Apperley, J.
    Michallet, M.
    Grigg, A.
    Silver, R.
    Niederwieser, D.
    De Witte, T.
    Olavarria, E.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S240 - S240
  • [25] Effect of prior therapy with Nilotinib or Dasatinib on the outcome after allogeneic stem cell transplantation for patients with chronic myeloid leukaemia
    Schleuning, M.
    Olavarria, E.
    Scholten, M.
    van Biezen, A.
    Michallet, M.
    Nagler, A.
    Hochhaus, A.
    Grigg, A.
    Silver, R.
    Schuld, P.
    Niederwieser, D.
    de Witte, T.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S32 - S32
  • [26] The role of stem cell transplantation in paediatric patients with chronic myeloid leukaemia in the era of tyrosine kinase inhibitors
    Suttorp, M.
    Tauer, J. T.
    von Neuhoff, N.
    Nowasz, C.
    Bradtke, J.
    Teigler-Schlegel, A.
    Thiede, C.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S52 - S52
  • [27] Use of Second Generation Tyrosine Kinase Inhibitors for Second-Line Treatment of Chronic Myeloid Leukemia After Imatinib Failure
    Buyukasik, Yahya
    UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02): : 4 - 9
  • [28] Imatinib for chronic myeloid leukaemia relapsing after allogeneic bone marrow transplantation
    Lucesole, M
    Garuti, A
    Sessarego, M
    Di Grazia, C
    van Lint, MT
    Dominietto, A
    Raiola, AM
    Lamparelli, T
    Gualandi, F
    Occhini, D
    Bregante, S
    Galbusera, V
    Bacigalupo, A
    BONE MARROW TRANSPLANTATION, 2004, 33 : S150 - S150
  • [29] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
    A Bacigalupo
    Leukemia, 2003, 17 : 1722 - 1722
  • [30] Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia
    E Olavarria
    O G Ottmann
    M Deininger
    R E Clark
    G Bandini
    J Byrne
    J Lipton
    A Vitek
    M Michallet
    W Siegert
    A Ullmann
    B Wassmann
    D Niederwieser
    T Fischer
    Leukemia, 2003, 17 : 1707 - 1712
12345